Ep. 319: “Building Better iPSCs” Featuring Dr. Andrew Gaffney

In this episode of The Stem Cell Podcast, hosts Dr. Dalon James and Dr. Arun Sharma welcome Dr. Andrew Gaffney, Vice President of the iPSC Platform at Stem Cell Technologies, to discuss the critical challenges and advancements in iPSC research and commercialization. The conversation centers on three pillars: building genetically diverse iPSC repositories to improve disease modeling and drug screening equity, ensuring reproducibility through standardized quality benchmarking, and navigating the complex intellectual property (IP) landscape to enable clinical translation. Gaffney emphasizes that the 20th anniversary of iPSCs is not a time for celebration but the beginning of a more rigorous phase focused on quality, diversity, and regulatory readiness. The episode also covers recent breakthroughs in transgene-free embryo models, CRISPR-engineered hematopoietic stem cells for multi-pathogen vaccines, and chemical reprogramming that leverages p53 for genomic stability—highlighting the growing synergy between engineering and biology in stem cell science. The hosts reflect on the need for multiple 'shots on goal' in regenerative medicine, from direct cardiac reprogramming to organoid development, while underscoring the importance of foundational tools and responsible innovation. Key takeaways include: (1) Genetic diversity in iPSC lines is essential for equitable and reliable disease modeling and drug screening; (2) Standardized, deep-characterized reference iPSC lines are critical for true 'plug-and-play' reproducibility across labs; (3) Early freedom-to-operate (FTO) analysis is non-negotiable for translational success to avoid costly IP roadblocks; (4) Chemical reprogramming offers a safer, more physiologically aligned alternative to transgene-based methods by preserving p53’s tumor-suppressive role; (5) Engineering approaches—like microfluidic gradients and gene editing—are enabling unprecedented control over cell fate and tissue organization. The episode concludes with a call to action for researchers to think beyond discovery and consider the full translational pipeline from bench to bedside.